Leading innovative pharmaceutical companies, including BeiGene and Hansoh Pharmaceutical, have unveiled their first-half financial results. The market's attention has centered on key metrics such as revenue from novel drugs, advancements in the R&D pipeline, and strategies for overseas expansion. Industry experts highlight that China's biotech sector has achieved a significant leap, transitioning from being mere "followers" to becoming "leaders" in the global arena. The thriving innovative drug industry is poised for further growth, with the acceleration of its "innovation + internationalization" strategy emerging as the cornerstone of development within the pharmaceutical sector.
